Effect of mannose chain length on targeting of glucocerebrosidase for enzyme replacement therapy of Gaucher disease
Open Access
- 24 January 2007
- journal article
- research article
- Published by Oxford University Press (OUP) in Glycobiology
- Vol. 17 (5) , 467-478
Abstract
Recombinant human glucocerebrosidase (imiglucerase, Cerezyme®) is used in enzyme replacement therapy for Gaucher disease. Complex oligosaccharides present on Chinese hamster ovary cell-expressed glucocerebrosidase (GCase) are enzymatically remodeled into a mannose core, facilitating mannose receptor-mediated uptake into macrophages. Alternative expression systems could be used to produce GCase containing larger oligomannose structures, offering the possibility of an improvement in targeting to macrophages. A secondary advantage of these expression systems would be to eliminate the need for carbohydrate remodeling. Here, multiple expression systems were used to produce GCase containing primarily terminal oligomannose, from Man2 to Man9. GCase from these multiple expression systems was compared to Cerezyme® with respect to affinity for mannose receptor and serum mannose-binding lectin (MBL), macrophage uptake, and intracellular half-life. In vivo studies comparing clearance and targeting of Cerezyme® and the Man9 form of GCase were carried out in a Gaucher mouse model (D409V/null). Mannose receptor binding, macrophage uptake, and in vivo targeting were similar for all forms of GCase. Increased MBL binding was observed for all forms of GCase having larger mannose structures than those of Cerezyme®, which could influence pharmacokinetic behavior. These studies demonstrate that although alternative cell expression systems are effective for producing oligomannose-terminated glucocerebrosidase, there is no biochemical or pharmacological advantage in producing GCase with an increased number of mannose residues. The display of alternative carbohydrate structures on GCase expressed in these systems also runs the risk of undesirable consequences, such as an increase in MBL binding or a possible increase in immunogenicity due to the presentation of non-mammalian glycans.Keywords
This publication has 42 references indexed in Scilit:
- Measurement of lysosomal glucocerebrosidase activity in mouse liver using a fluorescence-activated cell sorter assayAnalytical Biochemistry, 2004
- Immunoreactivity in mammals of two typical plant glyco-epitopes, core alpha(1,3)-fucose and core xyloseGlycobiology, 2002
- Production of recombinant proteins in fermenter cultures of the yeast Pichia pastorisCurrent Opinion in Biotechnology, 2002
- Insect cells as hosts for the expression of recombinant glycoproteinsGlycoconjugate Journal, 1999
- High resolution and high sensitivity methods for oligosaccharide mapping and characterization by normal phase high performance liquid chromatography following derivatization with highly fluorescent anthranilic acidGlycobiology, 1998
- Modifying exogenous glucocerebrosidase for effective replacement therapy in Gaucher diseaseJournal of Inherited Metabolic Disease, 1994
- Replacement Therapy for Inherited Enzyme Deficiency — Macrophage-Targeted Glucocerebrosidase for Gaucher's DiseaseNew England Journal of Medicine, 1991
- Therapeutic response to intravenous infusions of glucocerebrosidase in a patient with Gaucher disease.Proceedings of the National Academy of Sciences, 1990
- Gaucher diseaseBlood Reviews, 1988
- Human β-glucuronidase: In vivo clearance and in vitro uptake by a glycoprotein recognition system on reticuloendothelial cellsCell, 1978